Dianthus Therapeutics, Inc.
NCM: DNTHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Dianthus Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DNTH Z-Score →About Dianthus Therapeutics, Inc.
Healthcare
Biotechnology
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
📊 Fundamental Analysis
Dianthus Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -78.6% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -38.4%, which indicates that capital utilization is currently under pressure.
At a current price of $89.77, DNTH currently trades near the top of its 52-week range (97%) (Range: $16.64 - $92.27).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$4.89B
Trailing P/E
--
Forward P/E
-17.55
Beta (5Y)
0.21
52W High
$92.27
52W Low
$16.64
Avg Volume
1.08M
Day High
Day Low